Strides Completes Acquisition Of Endo US Facility And ANDAs
The $24m Deal Involves Manufacturing Site And Multiple ANDAs From Endo
• By Akriti Seth
Generate a summary of this article
Listen to this article
Two months after announcing the deal, Strides Pharma Science has closed its acquisition of a US manufacturing site and basket of ANDAs from Endo, doubling the company’s burgeoning US business and providing much-needed cash to the US-based company.
Strides and Endo successfully execute the partnership deal • Source: Alamy
Strides Pharma Science Limited has bolstered its growing operations in the US after completing its $24m acquisition of Endo’s manufacturing site in Chestnut Ridge, New York, alongside a basket of abbreviated new drug application across multiple therapies.
The Indian firm announced the deal in August this year, noting that its US business had “seen a significant ramp...
Stay ahead of every shift in generics and biosimilars.
Generics Bulletin brings you the latest updates that matter for the off-patent industry.
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.